Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Public ClinicalTrials.gov record NCT03786081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
Study identification
- NCT ID
- NCT03786081
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2019
- Primary completion
- Mar 18, 2026
- Completion
- Mar 18, 2026
- Last update posted
- Jul 21, 2026
2019 – 2026
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Phoenix | Arizona | 85016 | — |
| Univ California, Irvine Medical Center | Orange | California | 92868 | — |
| Olive View - UCLA Research and Education Institute | Sylmar | California | 91342 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| University of Chicago | Chicago | Illinois | 60525 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Oschner Clinic | New Orleans | Louisiana | 70121 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | — |
| Montana Cancer Consortium | Billings | Montana | 59102 | — |
| SUNY Downstate Medical Center | Brooklyn | New York | 11203 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| University of Cincinnati Physicians Group | Cincinnati | Ohio | 45206 | — |
| Cleveland Clinic | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University Wexner Medical Center | Hilliard | Ohio | 43026 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| Brown University - Women's and Infant Hospital | Providence | Rhode Island | 02905 | — |
| St Francis Hospital Cancer Center | Greenville | South Carolina | 29607 | — |
| Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
| Carilion Clinic | Roanoke | Virginia | 24016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03786081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03786081 live on ClinicalTrials.gov.